Fig. 1From: Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete responseClinical appearance and successful treatment of the IRAE. a Ulcerative vulvitis six months after initial IRAE symptoms; biopsy shown in Fig. 2 was taken. b Successful management of IRAE with topical corticosteroidsBack to article page